Tuberculosis
T-SPOT®.
TB
Economic Impact
Guidelines
The Learning Zone
Healthcare FAQs
About Tuberculosis
Active TB Disease and Latent TB Infection
Diagnosing Tuberculosis
Why Choose T-SPOT®.
TB
TB Vaccination & Treatment
Patient Groups
Patient FAQs
Media Requests
The World Health Organization (WHO) estimates that more than one third of the world’s population is infected with Mycobacterium tuberculosis.
Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell
Xtend
®
reagent
Independent study demonstrates that T-SPOT
®
.
TB
assay outperforms TST in predicting TB disease
The T-SPOT
®
.
TB
Test Now Included in New CDC Guidelines
Oxford International
About
T-SPOT® Technology
Values
Executive Team
Board Of Directors
Investors
Products
T-SPOT®.
TB
T-Cell
Xtend
®
T-SPOT®.
Service
(now Oxford Diagnostic Laboratories)
Product Support
News and Events
Events
Press Releases
Resources
FAQ - Healthcare Professionals
FAQ - Patients
Downloads
Links
Careers
Values
Open Positions
Apply Online
Contact
Worldwide Distributors
Recent News
Results confirm T-SPOT®.TB is not affected by low CD4 count HIV infected subjects
Healthcare
Tuberculosis
T-SPOT®.
TB
Economic Impact
Guidelines
The Learning Zone
Healthcare FAQs
Patients
About Tuberculosis
Active TB Disease and Latent TB Infection
Diagnosing Tuberculosis
Why Choose T-SPOT®.
TB
TB Vaccination & Treatment
Patient Groups
Patient FAQs
Media
Media Requests
Terms of Use
Privacy Policy
Send to a Friend - International
Email Sign Up - International
International Search Results
Email Success
Email Failure
Get Email Updates
